schizophrenia
Conditions
Interventions
First-episode schizophrenia
blonanserin treatment group Patients were received blonanserin, and the dosage is adjusted to between 2 and 24 mg/day.
Control group Chronic patients with schizophrenia who were treat
aripiprazole treatment group Patients were received aripiprazole, and the dosage is adjusted to between 3 and 30 mg/day.
Control group Chronic patients with schizophrenia who were treat
Sponsors
Department of Neuropsychiatry St. Marianna University School of Medicine
Ofuji hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) aged 16 to 40 years 2) meeting DSM-IV-TR criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder 3) experiencing their first episode of psychosis for at least 1 month and less than 5 years 4) no history of antipsychotic exposure or, if previously treated, a total lifetime of antipsychotic treatment of less than 16 weeks, and no antipsychotic administration for 12 weeks before participating in the study 5)inpatient or outpatient 6) patients who gave informed consent
Exclusion criteria
Exclusion criteria: 1) patients who had been treated with blonanserin or aripiprazole before study entry 2) comorbid central nervous system disorder 3) meeting DSM-IV-TR criteria for alcohol or other substance dependence 4) meeting DSM-IV-TR criteria for mental retardation 5) symptomatic or organic psychosis (including dementia) 6) taking tricyclic antidepressants 7) treatment with electroconvulsive therapy in the 12 weeks preceding the study 8) treatment with long-acting antipsychotics in the 12 weeks preceding the study 9) patients who are not voluntarily hospitalized 10) active expression of suicidal or homicidal ideation 11) pregnancy or breast feeding 12) inability to understand the study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive function: Brief Assessment of Cognition in Schizophrenia-Japanese version (BACS-J) | — |
Secondary
| Measure | Time frame |
|---|---|
| Psychopathology: Positive And Negative Syndrome Scale (PANSS), Clinical Global Impression- Severity (CGI-S) Functional ability: Schizophrenia Cognitive Rating Scale- Japanese version (SCoRS-J), University of California, San Diego, Performance- Based Skills Assessment (UPSA) Subjective assessments: Schizophrenia Quality of Life Scale-Japanese version (SQLS-J), Subjective Well-being under Neuroleptic drug treatment Short form, Japanese version (SWNS-J) Adverse effects: Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS),Weight Laboratory tests | — |
Countries
Japan
Contacts
Public ContactTomomi Tenjin
St. Marianna University School of Medicine Department of Neuropsychiatry
Outcome results
None listed